817 related articles for article (PubMed ID: 15980149)
1. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Klebanoff CA; Gattinoni L; Torabi-Parizi P; Kerstann K; Cardones AR; Finkelstein SE; Palmer DC; Antony PA; Hwang ST; Rosenberg SA; Waldmann TA; Restifo NP
Proc Natl Acad Sci U S A; 2005 Jul; 102(27):9571-6. PubMed ID: 15980149
[TBL] [Abstract][Full Text] [Related]
2. The roles of CD8 central and effector memory T-cell subsets in allograft rejection.
Oberbarnscheidt MH; Ng YH; Chalasani G
Am J Transplant; 2008 Sep; 8(9):1809-18. PubMed ID: 18671680
[TBL] [Abstract][Full Text] [Related]
3. IL-15 transpresentation augments CD8+ T cell activation and is required for optimal recall responses by central memory CD8+ T cells.
Kokaji AI; Hockley DL; Kane KP
J Immunol; 2008 Apr; 180(7):4391-401. PubMed ID: 18354159
[TBL] [Abstract][Full Text] [Related]
4. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
[TBL] [Abstract][Full Text] [Related]
5. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner.
Charlton JJ; Chatzidakis I; Tsoukatou D; Boumpas DT; Garinis GA; Mamalaki C
J Immunol; 2013 Jun; 190(12):6104-14. PubMed ID: 23686498
[TBL] [Abstract][Full Text] [Related]
7. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Klebanoff CA; Finkelstein SE; Surman DR; Lichtman MK; Gattinoni L; Theoret MR; Grewal N; Spiess PJ; Antony PA; Palmer DC; Tagaya Y; Rosenberg SA; Waldmann TA; Restifo NP
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1969-74. PubMed ID: 14762166
[TBL] [Abstract][Full Text] [Related]
8. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV
J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377
[TBL] [Abstract][Full Text] [Related]
9. The rationale for the IL-2-independent generation of the self-renewing central memory CD8+ T cells.
Fearon DT; Carr JM; Telaranta A; Carrasco MJ; Thaventhiran JE
Immunol Rev; 2006 Jun; 211():104-18. PubMed ID: 16824121
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Kammula US
Cancer Res; 2015 Aug; 75(16):3216-26. PubMed ID: 26100671
[TBL] [Abstract][Full Text] [Related]
11. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
12. Effector function-deficient memory CD8+ T cells clonally expand in the liver and give rise to peripheral memory CD8+ T cells.
Su YC; Lee CC; Kung JT
J Immunol; 2010 Dec; 185(12):7498-506. PubMed ID: 21078905
[TBL] [Abstract][Full Text] [Related]
13. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice.
Wang X; Berger C; Wong CW; Forman SJ; Riddell SR; Jensen MC
Blood; 2011 Feb; 117(6):1888-98. PubMed ID: 21123821
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
Mueller K; Schweier O; Pircher H
Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.
Teague RM; Sather BD; Sacks JA; Huang MZ; Dossett ML; Morimoto J; Tan X; Sutton SE; Cooke MP; Ohlén C; Greenberg PD
Nat Med; 2006 Mar; 12(3):335-41. PubMed ID: 16474399
[TBL] [Abstract][Full Text] [Related]
16. IL-15-dependent upregulation of GITR on CD8 memory phenotype T cells in the bone marrow relative to spleen and lymph node suggests the bone marrow as a site of superior bioavailability of IL-15.
Snell LM; Lin GH; Watts TH
J Immunol; 2012 Jun; 188(12):5915-23. PubMed ID: 22581858
[TBL] [Abstract][Full Text] [Related]
17. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes.
Romero P; Zippelius A; Kurth I; Pittet MJ; Touvrey C; Iancu EM; Corthesy P; Devevre E; Speiser DE; Rufer N
J Immunol; 2007 Apr; 178(7):4112-9. PubMed ID: 17371966
[TBL] [Abstract][Full Text] [Related]
18. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
19. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
Hinrichs CS; Borman ZA; Cassard L; Gattinoni L; Spolski R; Yu Z; Sanchez-Perez L; Muranski P; Kern SJ; Logun C; Palmer DC; Ji Y; Reger RN; Leonard WJ; Danner RL; Rosenberg SA; Restifo NP
Proc Natl Acad Sci U S A; 2009 Oct; 106(41):17469-74. PubMed ID: 19805141
[TBL] [Abstract][Full Text] [Related]
20. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
